Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2013-03-25 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
第二届董事会第十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 16th meeting of the 2nd Board of Directors of Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes approvals of the 2012 General Manager's Work Report, 2012 Board Work Report, 2012 Annual Report and its summary, profit distribution plan, appointment of auditors, internal control self-evaluation report, amendments to the Articles of Association, and other corporate governance matters. The document references the 2012 Annual Report multiple times and states that these reports will be submitted to the 2012 Annual General Meeting for approval. The document is a formal board meeting resolution announcement rather than the full annual report itself. It contains no full financial statements or detailed financial data but rather decisions and approvals related to the annual report and other corporate matters. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management. The document length (5586 characters) and content confirm it is not the full annual report (10-K) but a board meeting resolution announcement.
2013-03-25 Chinese
招商证券股份有限公司关于公司2012年度募集资金使用与存放情况专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项核查报告" (special inspection report) by 招商证券股份有限公司 regarding the 2012年度募集资金使用与存放情况 (2012 annual use and deposit status of raised funds) of 深圳信立泰药业股份有限公司. It details the use, management, and storage of funds raised from the company's IPO in 2009, including detailed financial figures, project investment progress, changes in project locations and investment amounts, and compliance with regulatory requirements. The document is a specialized audit or verification report on the use of raised funds, prepared by the sponsor (招商证券) as required by Chinese securities regulations. It is not a full annual report, earnings release, or general regulatory filing. It is a standalone audit-type report focused on the use of IPO proceeds and compliance with fundraising regulations. Therefore, it fits best under the category Audit Report / Information (AR). The document length (over 10,000 characters) and detailed financial data confirm it is a full report, not just an announcement or certification. FY 2012
2013-03-25 Chinese
独立董事关于公司有关事项所发表的独立意见
Audit Report / Information Classification · 95% confidence The document is titled as an independent opinion from the independent directors of Shenzhen Salubris Pharmaceuticals Co., Ltd. It references compliance with company law, stock exchange listing rules, and company articles. The content includes independent opinions on the 2012 profit distribution plan, remuneration of directors and senior management for 2012, reappointment of the 2013 audit firm, use of raised funds in 2012, internal control self-evaluation report for 2012, and guarantees and related party fund occupation for 2012. The document is a formal statement of independent directors' opinions on various company matters related to the 2012 fiscal year, including audit and governance issues. It does not contain full financial statements or detailed audit reports but rather the independent directors' opinions on these matters. This fits the category of Audit Report / Information (AR), which includes standalone audit reports, applied accounting principles, and related opinions, excluding full annual reports. The document length is short (1374 characters), but it is not merely an announcement or certification; it is a substantive independent opinion document. Therefore, the best classification is AR with high confidence. FY 2012
2013-03-25 Chinese
2012年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2012 年度报告摘要" which translates to "2012 Annual Report Summary". It contains detailed financial data for the year 2012, including income, profit, cash flow, assets, liabilities, and management discussion and analysis. The document includes comprehensive financial statements and analysis for the full fiscal year 2012, which is characteristic of an Annual Report. The length of the document (12,673 characters) and the depth of financial and operational information confirm it is the report itself, not just an announcement or summary notice. Therefore, the document fits the definition of an Annual Report (10-K). FY 2012
2013-03-25 Chinese
关于公司募集资金年度存放与实际使用情况的鉴证报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from an accounting firm (RSM China Certified Public Accountants) providing an assurance opinion on the annual use and deposit of raised funds by Shenzhen Salubris Pharmaceuticals Co., Ltd. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange regarding the management and use of raised funds. The document includes detailed financial data on the raised funds, their usage, project progress, changes in project implementation, and investment outcomes for the fiscal year ending December 31, 2012. It is not a full annual report or earnings release but a specialized assurance report on the use of capital raised by the company. This fits the definition of an Audit Report / Information (AR), which includes standalone audit or assurance reports related to accounting and regulatory compliance, excluding full annual reports. The document length (15,000 characters) and content confirm it is the report itself, not just an announcement or certification letter. Therefore, the correct classification is AR with high confidence. FY 2012
2013-03-25 Chinese
2012年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2012 年度报告全文" which translates to "2012 Annual Report Full Text" for Shenzhen Salubris Pharmaceuticals Co., Ltd. It contains detailed sections typical of an annual report, including company overview, financial data and indicators, board of directors report, major events, shareholder information, governance, internal control, and financial statements. The document includes comprehensive financial data, management discussion, and analysis for the full fiscal year 2012. It is not a brief announcement or a presentation but a full detailed report. Therefore, it fits the definition of an Annual Report (10-K). FY 2012
2013-03-25 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.